National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Fampridine (Fampyra®) for the improvement of walking in adult patients with multiple sclerosis with walking disability (EDSS 4-7).

Rapid Review

Commenced Completed Outcome
01/09/2011 September 2011 Full Pharmacoeconomic Evaluation Recommended

Pharmacoeconomic Evaluation

Commenced Completed Outcome
23/05/2012 17/08/2012  Reimbursement not recommended

As the manufacturer is unable to demonstrate the cost-effectiveness of fampridine we are unable to recommend reimbursement

Fampridine (Fampyra®) Summary